Back to dashboard
All PlansCoverageMedium impact

Proteogenomic Testing for Patients With Cancer

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology, Pathology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

New medical policy A.2.04.140 establishes coverage guidelines for proteogenomic testing in cancer patients, including the GPS Cancer test. This policy defines when proteogenomic testing is considered medically necessary and outlines the integration of genomic, proteomic, and transcriptomic information for cancer diagnosis and treatment.

Action Required

Action needed
Immediately: Review new policy A.2.04.140 for proteogenomic testing coverage criteria. Billing team should verify coverage requirements and any prior authorization needs for GPS Cancer test and other proteogenomic testing before submitting claims. Update staff on new testing definitions and coverage guidelines for cancer patients requiring proteogenomic analysis.

Related policy hubs